Kolexia
Planchard David Pneumologie
Planchard David
Pneumologie
Gustave-Roussy
Villejuif, France
835 Activités
6.4 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du poumon Carcinome pulmonaire non à petites cellules Carcinome pulmonaire à petites cellules Métastase tumorale Mésothéliome Mésothéliome malin Carcinomes Cellules tumorales circulantes Tumeurs du cerveau

Collaborateurs

Voir plus
Besse Benjamin
Besse Benjamin
Gustave-Roussy, Villejuif, France
Mezquita Perez Laura
Mezquita Perez Laura
Gustave-Roussy, Villejuif, France
Soria Jean-Charles
Soria Jean-Charles
Gustave-Roussy, Villejuif, France
Caramella Caroline
Caramella Caroline
Gh Paris Site Saint Joseph, Paris, France

Industries

Voir plus
AstraZeneca
45 collaboration(s)
Dernière en 2023
Janssen
23 collaboration(s)
Dernière en 2023
Pfizer
20 collaboration(s)
Dernière en 2023
Roche
17 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors: A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants With BRAF and/or NRAS Mutation-positive Solid Tumors.
Essai Clinique (Kinnate Biopharma)   11 mars 2024
ENCO-BRAF: A Phase II Study of the BRAF Inhibitor Encorafenib in Combination With the MEK Inhibitor Binimetinib in Patients With BRAFV600E-mutant Metastatic Non-small Cell Lung Cancer
Essai Clinique (Intergroupe Francophone de Cancérologie Thoracique)   06 mars 2024
FLAURA2: A Phase III, Open-label, Randomized Study of Osimertinib With or Without Platinum Plus Pemetrexed Chemo, as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA2).
Essai Clinique (AstraZeneca)   12 février 2024
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158): A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)
Essai Clinique (Merck & Co.)   02 février 2024
Osimertinib with Chemotherapy in EGFR-Mutated NSCLC. Reply.
The New England journal of medicine   02 février 2024
DESTINY-LUNG02: A Phase 2, Multicenter, Randomized Study of Trastuzumab Deruxtecan in Subjects With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (DESTINY-LUNG02)
Essai Clinique (Daiichi Sankyo)   26 janvier 2024
Treatment decision for recurrences in non-small cell lung cancer during or after adjuvant osimertinib: an international Delphi consensus report.
Frontiers in oncology   23 janvier 2024
AURA: Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AZD9291 in Patients With Advanced Non Small Cell Lung Cancer Who Progressed on Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent
Essai Clinique (AstraZeneca)   17 janvier 2024
FLAURA: A Phase III, Double-blind, Randomised Study to Assess the Safety and Efficacy of AZD9291 Versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First Line Treatment in Patients With Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non Small Cell Lung Cancer.
Essai Clinique (AstraZeneca)   15 janvier 2024
Cindy souffre d'un cancer du poumon métastasé
Youtube @ Fondation pour la Recherche Médicale (FRM)   12 janvier 2024